 Results to be shared on August 17th during Needhams Virtual Med Tech Diagnostics ConferenceHINGHAM, Mass., Aug. 13, 2020 GLOBE NEWSWIRE -- At the upcoming Needham Virtual Med Tech Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. Nasdaq: MBOT, will provide initial results of a feasibility animal study performed using the Companys LIBERTY Robotic System. Harel Gadot, CEO, President and Chairman along with other members of the management team are scheduled to conduct one-on-one meetings during the day. The investor presentation, which will highlight the initial results of the feasibility animal study, will be made available prior to the first meeting and accessed via the Investors section, under Presentation Resources of the Companys website at Companys LIBERTY robotic system, which was unveiled in January 2020, is the worlds first fully disposable robotic system which features a unique compact design; with the capability to be operated remotely, it is being designed to reduce radiation exposure as well as the physical strain to the physician. Incorporating the technology the Company acquired from CardioSert into the LIBERTY Robotic System, it has the potential to eliminate the use of multiple consumables through its One Done capabilities.About Microbot MedicalMicrobot Medical Inc. NASDAQ: MBOT is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbots current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio MGPP.Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at HarborStatements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial andor operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects and estimates should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development andor commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading Risk Factors in Microbot Medicals periodic reports filed with the Securities and Exchange Commission SEC and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SECs web site at Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.Investor Contact: Michael Polyviou EVC Group 732-933-2754 